The future of genome-based medicine

Morris, Q; Brenner, SE; Listgarten, J; Stegle, O

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Conference Paper

The future of genome-based medicine

MPS-Authors

/persons/resource/persons84969

Stegle, O
Department Molecular Biology, Max Planck Institute for Developmental Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Morris, Q., Brenner, S., Listgarten, J., & Stegle, O. (2013). The future of genome-based medicine. In R. Altman, A. Dunker, L. Hunter, T. Murray, & T. Klein (Eds.), Biocomputing 2013: Pacific Symposium on Biocomputing (pp. 456-458). Singapore: World Scientific Publishing Company.

Cite as: https://hdl.handle.net/21.11116/0000-0010-5B04-4

Abstract

There has been unprecedented public investment in sequencing human and cancer genomes in the hopes of understanding disease [1, 2]. At the same time, large genome-wide association studies have helped elucidating the genetic underpinning of common diseases, identifying thousands of putative disease relevant loci [7, 8]. Complementary molecular profiling studies have revealed that several of these loci are co-associated with individual mRNA levels, suggesting candidate pathways that are putative mediators of genetic signals [7]. Coupled with the public investment, there is considerable personal investment in genetic profiling, being offered by companies such as 23andMe, deCODEme and others. Although this work has led to amazing discoveries, such as the surprising genetic, subclonal diversity within tumor populations (e.g., [3–5]), it’s not clear how much how these insights will improve personalization of medicine.